109 related articles for article (PubMed ID: 29782348)
1. Renal Ewing sarcoma treated with apatinib.
Zhao Y; Chen Y; Cheng K; Li ZP; Zeng H; Liu JY
Anticancer Drugs; 2018 Aug; 29(7):702-704. PubMed ID: 29782348
[TBL] [Abstract][Full Text] [Related]
2. Apatinib for advanced sarcoma: results from multiple institutions' off-label use in China.
Xie L; Guo W; Wang Y; Yan T; Ji T; Xu J
BMC Cancer; 2018 Apr; 18(1):396. PubMed ID: 29625604
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of apatinib monotherapy in metastatic renal cell carcinoma (mRCC) patients: A single-arm observational study.
Cui Y; Cao Y; Cao M; Chen X; Liu G; Chen H
Urol Oncol; 2020 Dec; 38(12):936.e1-936.e6. PubMed ID: 32839081
[TBL] [Abstract][Full Text] [Related]
4. The Successful Treatment of Metastatic Extraosseous Ewing Sarcoma with Pazopanib.
Mori Y; Kinoshita S; Kanamori T; Kataoka H; Joh T; Iida S; Takemoto M; Kondo M; Kuroda J; Komatsu H
Intern Med; 2018 Sep; 57(18):2753-2757. PubMed ID: 29780156
[TBL] [Abstract][Full Text] [Related]
5. Tislelizumab combined with apatinib in the treatment of advanced renal clear cell carcinoma: a case report.
Qu F; Wu S; Zhang J
Anticancer Drugs; 2022 Jan; 33(1):e834-e839. PubMed ID: 34459463
[TBL] [Abstract][Full Text] [Related]
6. Primary Ewing's sarcoma of the kidney: a case report.
Vrdoljak DV; Sitić S; Stanec M; Oresić T; Balja MP; Ramljak V; Gutesa I; Ramić S; Knezević F
Coll Antropol; 2012 Jun; 36(2):673-6. PubMed ID: 22856262
[TBL] [Abstract][Full Text] [Related]
7. Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction.
Li J; Qin S; Xu J; Xiong J; Wu C; Bai Y; Liu W; Tong J; Liu Y; Xu R; Wang Z; Wang Q; Ouyang X; Yang Y; Ba Y; Liang J; Lin X; Luo D; Zheng R; Wang X; Sun G; Wang L; Zheng L; Guo H; Wu J; Xu N; Yang J; Zhang H; Cheng Y; Wang N; Chen L; Fan Z; Sun P; Yu H
J Clin Oncol; 2016 May; 34(13):1448-54. PubMed ID: 26884585
[TBL] [Abstract][Full Text] [Related]
8. A rare entity of Primary Ewing sarcoma in kidney.
Cheng L; Xu Y; Song H; Huang H; Zhuo D
BMC Surg; 2020 Nov; 20(1):280. PubMed ID: 33176766
[TBL] [Abstract][Full Text] [Related]
9. A Pilot Study of Apatinib as Third-Line Treatment in Patients With Heavily Treated Metastatic Colorectal Cancer.
Liang L; Wang L; Zhu P; Xia Y; Qiao Y; Wu J; Zhuang W; Fei J; Wen Y; Jiang X
Clin Colorectal Cancer; 2018 Sep; 17(3):e443-e449. PubMed ID: 29576426
[TBL] [Abstract][Full Text] [Related]
10. Application effect of apatinib in patients with failure of standard treatment for advanced malignant tumours.
Liu G; Wang C; He Y; E M
BMC Pharmacol Toxicol; 2019 Oct; 20(1):61. PubMed ID: 31661009
[TBL] [Abstract][Full Text] [Related]
11. Ewing sarcoma/primitive neuroectodermal tumor of the kidney treated with chemotherapy including ifosfamide.
Yoshihara H; Kamiya T; Hosoya Y; Hasegawa D; Ogawa C; Asanuma H; Mizuno R; Hosoya R; Manabe A
Pediatr Int; 2016 Aug; 58(8):766-9. PubMed ID: 27324740
[TBL] [Abstract][Full Text] [Related]
12. [Clinical efficacy and safety of apatinib combined with chemotherapy for osteosarcoma and soft tissue sarcoma with pulmonary metastasis].
Li SL; Yang QK; Chen P; Zheng K; Wang W; Pei Y; Zhang XJ
Zhonghua Zhong Liu Za Zhi; 2019 Apr; 41(4):309-314. PubMed ID: 31014058
[No Abstract] [Full Text] [Related]
13. Frequent dose interruptions are required for patients receiving oral kinase inhibitor therapy for advanced renal cell carcinoma.
La Vine DB; Coleman TA; Davis CH; Carbonell CE; Davis WB
Am J Clin Oncol; 2010 Jun; 33(3):217-20. PubMed ID: 19745694
[TBL] [Abstract][Full Text] [Related]
14. Cabozantinib approved for first-line treatment of advanced renal cell carcinoma.
Clin Adv Hematol Oncol; 2018 Feb; 16(2):96. PubMed ID: 29741507
[No Abstract] [Full Text] [Related]
15. Phase II study of olaparib in patients with refractory Ewing sarcoma following failure of standard chemotherapy.
Choy E; Butrynski JE; Harmon DC; Morgan JA; George S; Wagner AJ; D'Adamo D; Cote GM; Flamand Y; Benes CH; Haber DA; Baselga JM; Demetri GD
BMC Cancer; 2014 Nov; 14():813. PubMed ID: 25374341
[TBL] [Abstract][Full Text] [Related]
16. A phase II study of apatinib in patients with recurrent epithelial ovarian cancer.
Miao M; Deng G; Luo S; Zhou J; Chen L; Yang J; He J; Li J; Yao J; Tan S; Tang J
Gynecol Oncol; 2018 Feb; 148(2):286-290. PubMed ID: 29248198
[TBL] [Abstract][Full Text] [Related]
17. Antiangiogenic therapy for Wilms tumor in an adult and literature review.
Wang J; Fan S; Feng Y; Zhang H; Zou W; Hu C
Anticancer Drugs; 2019 Jul; 30(6):640-645. PubMed ID: 30985306
[TBL] [Abstract][Full Text] [Related]
18. Apatinib in gastric carcinoma: A case report of partial response for first-line treatment in advanced disease.
Wang Y; Bi M; Zhang H; Gao Z; Zhou H; Chang S
Asia Pac J Clin Oncol; 2017 Oct; 13(5):e528-e530. PubMed ID: 28028915
[TBL] [Abstract][Full Text] [Related]
19. Successful treatment of advanced pancreatic liposarcoma with apatinib: A case report and literature review.
Han T; Luan Y; Xu Y; Yang X; Li J; Liu R; Li Q; Zheng Z
Cancer Biol Ther; 2017 Sep; 18(9):635-639. PubMed ID: 28678611
[TBL] [Abstract][Full Text] [Related]
20. The correlation between the incidence of adverse events and progression-free survival in patients treated with cabozantinib for metastatic renal cell carcinoma (mRCC).
Kucharz J; Dumnicka P; Kusnierz-Cabala B; Demkow T; Wiechno P
Med Oncol; 2019 Jan; 36(2):19. PubMed ID: 30666498
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
